TY - JOUR. T1 - Histological margin assessment for breast ductal carcinoma in situ. T2 - Precision and implications. AU - Sigal-Zafrani, B.. AU - Klimberg, Vicki. PY - 2004/12. Y1 - 2004/12. UR - http://www.scopus.com/inward/record.url?scp=4944266356&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=4944266356&partnerID=8YFLogxK. M3 - Comment/debate. AN - SCOPUS:4944266356. VL - 15. SP - 312. EP - 313. JO - Breast Diseases. JF - Breast Diseases. SN - 1043-321X. IS - 3. ER - ...

New research from Amsterdam shows that women over the age of 50 who have been diagnosed with ductal carcinoma in situ have a higher chance of being alive ten years after their diagnosis than women in the general population, according to Science Daily. Ductal carcinoma in situ is considered a disease separate from breast cancer because it is at stage 0 and does not spread around the body. However, ductal carcinoma in situ can progress into full-blown breast cancer, which is why it is still treated with surgery or surgery in combination with radiation therapy.. The researcher Dr. Lotte Elshof presented findings at the European Cancer Congress 2017. Women who have been diagnosed with ductal carcinoma in situ should feel better about their future because of these findings, which show their longevity will not be impacted by this condition.. Dr. Jelle Wesseling and her team at the Netherlands Cancer Institute followed approximately 10,000 Dutch women with ductal carcinoma in situ between the years ...

Left breast upper outer quadrant suspicious morphology micro-calcifications. Core biopsy was done showing focal DCIS (clinging with comedo necrosis) of high grade. No evidence of stromal invasive component. The final diagnosis showed focal DCIS o...

approximately three-quarters of breast cancers Invasive ductal carcinoma - 55% of breast cancers Ductal carcinoma in situ - 13% Invasive lobular carcinoma - 5% The overall 5-year survival rate for both ... Ductal carcinoma in situ, on the other hand, is in itself harmless, although if untreated approximately 60% of these low grade DCIS lesions will become invasive over the course of 40 years in follow-up ...

Ductal carcinoma in situ (DCIS) is a non-obligate precursor lesion of invasive carcinoma of the breast. Current prognostic markers based on histopathological examination are unable to accurately predict which DCIS cases will progress to invasive carcinoma or recur after surgical excision. Epigenetic changes have been shown to be a significant driver of tumorigenesis, and DNA methylation of specific gene promoters provides predictive and prognostic markers in many types of cancer, including invasive breast cancer. In general, the spectrum of genes that are methylated in DCIS strongly resembles that seen in invasive ductal carcinoma. The identification of specific prognostic markers in DCIS remains elusive and awaits additional work investigating a large panel of methylatable genes by using sensitive and reproducible technologies. This review critically appraises the role of methylation in DCIS and its use as a biomarker ...

TY - JOUR. T1 - Treatment of low-risk ductal carcinoma in situ. T2 - is nothing better than something?. AU - Benson, John R.. AU - Jatoi, Ismail. AU - Toi, Masakazu. PY - 2016/10/1. Y1 - 2016/10/1. N2 - The heterogeneous nature of ductal carcinoma in situ has been emphasised by data for breast-cancer screening that show substantial increases in the detection of early-stage non-invasive breast cancer but no noteworthy change in the incidence of invasive and distant metastatic disease. Indolent non-progressive forms of ductal carcinoma in situ are managed according to similar surgical strategies as high-risk disease, with extent of resection dictated by radiological and pathological estimates of tumour dimensions. Although adjuvant treatments might be withheld for low-risk lesions, surgical treatments incur potential morbidity, especially when mastectomy and breast reconstruction are done for widespread low-grade or intermediate-grade ductal carcinoma in situ. Low rates of deaths from breast ...

Widespread screening mammography programmes mean that ductal carcinoma in situ (DCIS), a pre-invasive breast lesion, is now more frequently diagnosed. However, not all diagnosed DCIS lesions progress to invasive breast cancer, which presents a dilemma for clinicians. As such, there is much interest in studying DCIS in the laboratory, in order to help understand more about its biology and determine the characteristics of those that progress to invasion. Greater knowledge would lead to targeted and better DCIS treatment. Here, we outline some of the models available to study DCIS, with a particular focus on animal-free systems.. ...

RESULTS: 42 of the 99 lesions (42.4%) were invasive carcinomas, 57 (57.6%) were pure ductal carcinoma in situ (DCIS). 6 out of 99 (6.1%) lesions were triple negative, and 29 (29.3%) were HER2/neu positive. Successful first excision rate was 76/99 lesions (76.8%). Breast conservation was achieved in 73.7% (73/99). 10 women showed local recurrences without negatively impacting survival. The recurrences included round/punctate, amorphous, fine pleomorphic, and fine linear or fine-linear branching descriptors. The breast cancer-specific long-term survival rate was 91/94 (96.8%) for a mean follow-up of 81.4 months. The 3 patients who died due to breast carcinoma showed fine pleomorphic calcifications, and had nodal-positive invasive carcinoma at diagnosis ...

The micrometastasis was discovered because your surgeon performed an axillary lymph node dissection. A surgeon typically performs a lymph node dissection for ductal carcinoma in situ (DCIS) when there is extensive DCIS (like you had) or when a patient has a high-grade DCIS. When DCIS is high-grade, there are many dead cells in the duct, and the cells that are alive are very aberrant. In this situation there is a higher chance that microinvasion-a spot where the DCIS has crossed the line to invasion-has occurred.. It can be tricky to diagnose micrometastases in the sentinel node. Most likely your micrometastasis is due to cells that were displaced during surgery as opposed to an actual spread of cancer cells from the DCIS, especially if there was no invasion outside the duct. However, the only way to know this for sure is to have an expert in breast pathology determine if it is truly micrometastasis or if it is a displaced cell. This is why it is very important that you get a second opinion from ...

To summarize data on long-term ipsilateral local recurrence (LR) and breast cancer death rate (BCDR) for patients with ductal carcinoma in situ (DCIS) who received different treatments. Systematic review and study-level meta-analysis of prospective (n = 5) and retrospective (n = 21) studies of patients with pure DCIS and with median or mean follow-up time of ≥10 years. Meta-regression was performed to assess and adjust for effects of potential confounders - the average age of women, period of initial treatment, and of bias - follow-up duration on recurrence- and death-rates in each treatment group. LR and BCDR rates by local treatment used were reported. Outside of randomized trials, remaining studies were likely to have tailored patient treatment according to the clinical situation. Nine thousand four hundred and four DCIS cases in 9391 patients with 10-year follow-up were included. The adjusted meta-regression LR rate for mastectomy was 2.6 % (95 % CI, 0.8-4.5); breast-conserving surgery with

In conclusion, Dr. Lori Pierce, Vice Provost for Academic and Faculty Affairs and Professor of Radiation Oncology at the University of Michigan, says this article has summarized nicely the major challenges facing breast cancer patients and their physicians in the management of ductal carcinoma in situ (DCIS). DCIS is not an invasive disease but can progress to invasive breast cancer, and potentially impact survival, in a significant number of women if not adequately treated when diagnosed. And we know that for those patients treated with lumpectomy, radiation to follow will reduce the chance of DCIS returning and/or invasive disease developing by at least 50%. We also know, however, that in some patients, the likelihood that DCIS will progress to invasive disease is very low even in the absence of treatment. Unfortunately, we have not found a reproducible way to predict those who need to be treated and those who dont but many researchers are working on this very question. For now, clinicians ...

Mai, K. T., Perkins, D. G. and Mirsky, D. (2003), Location and Extent of Positive Resection Margins and Ductal Carcinoma in Situ in Lumpectomy Specimens of Ductal Breast Carcinoma Examined with a Microscopic Three-Dimensional View. The Breast Journal, 9: 33-38. doi: 10.1046/j.1524-4741.2003.09108.x ...

A small, early study suggests that a shorter, higher-dose radiation schedule after lumpectomy to remove DCIS (ductal carcinoma in situ) may reduce the risk of the cancer coming back (recurrence) just as much as a standard radiation treatment schedule.. The study was published in the June 2012 issue of the International Journal of Radiation Oncology*Biology*Physics. Read the abstract of Five Year Outcome of 145 Patients With Ductal Carcinoma In Situ (DCIS) After Accelerated Breast Radiotherapy.. DCIS is the most common form of non-invasive breast cancer. DCIS is called non-invasive because it hasnt spread beyond the milk duct into any normal surrounding breast tissue. DCIS isnt life-threatening, but having DCIS can increase the risk of developing an invasive breast cancer later on. DCIS usually is treated with surgery to remove the cancer, lumpectomy in most cases. After surgery, many women have radiation therapy.. Radiation therapy after breast cancer surgery is most commonly given as 25 ...

Although a precursor to breast cancer, DCIS can progress to become invasive disease and thus is normally treated with surgery, sometimes in combination with radiotherapy.. The team of researcher behind this new work, based at the Netherlands Cancer Institute (The Netherlands), hope that their results may provide reassurance to those women diagnosed with DCIS. Overall the findings indicate that although these individuals have an increased risk of dying from breast cancer, they actually have a slightly lower risk of dying from any cause.. Under the instruction of Jelle Wesseling (Netherlands Cancer Institute), the team analyzed data from 10,000 Dutch women diagnosed with DCIS from 1989 to 2004. They tracked the data from these patients over an average 10-year period and compared mortality rates with the expected mortality of the general population.. In terms of breast cancer mortality risk, the study demonstrated that DCIS patients had a 2.5% risk of dying from breast cancer 10 years after ...

There are a few things about ductal carcinoma in situ (DCIS) on which everyone agrees: Incidence increased dramatically with the advent of mammography screening, not all cases detected will go on to cause symptoms in the patients lifetime, and theres no proven way to tell which cases will progress.. But agreement often ends when it comes to clinical management. Should all cases be treated with surgery and radiation in the absence of proven markers to show which cases will progress? Or is watch-and-wait an option? Can existing tools be used to guide the decision?. Experts put their views on the line in a debate at the 66th Annual Cancer Symposium of the Society of Surgical Oncology, held March 6-9 in Washington, DC.. Battle Lines Drawn. All DCIS patients benefit from standard therapy, declared Thomas B. Julian, MD, a Professor of Surgery at Drexel and Temple Universities in Philadelphia, who took the pro-treatment position in the debate-format session.. DCIS is a heterogeneous disease that is ...

Mucinous breast carcinoma with a lobular neoplasia component : a subset with aberrant expression of cell adhesion and polarity molecules and lack of neuroendocrine differentiation(審査報告)Mucinous breast carcinoma with a lobular neoplasia component : a subset with aberrant expression of cell adhesion and polarity molecules and lack of neuroendocrine differentiation(審査報告) ...

Another interesting finding in our study is that women greater than 55 years of age with atypia had increased ER expression compared with younger women with atypia. This differs from the previous report by Shoker and colleagues (7) who found that ER expression was high in atypical ductal hyperplasia, ductal carcinoma in situ and lobular neoplasia regardless of age. The number of samples in that study was somewhat small; 23 cases of atypical hyperplasia, 43 cases of ductal carcinoma in situ, and 32 cases of lobular neoplasia. The authors suggested that in atypia and carcinoma in situ the regulation of ER expression may escape the normal age-related regulatory mechanisms. ER expression and relationship to age has also been studied in hyperplastic enlarged lobular units, a common alteration of the normal TDLU and potential precursor of breast cancer. Lee and colleagues (21) have shown that ER expression in hyperplastic enlarged lobular units is increased in postmenopausal woman compared with ...

Hollie Quinn suffered from the typical health complaints of an adult female; these included heartburn and acid reflux, along with painful cysts, vertigo and migraines.. Hollie says that she ate the typically American diet which was low in vegetables, high in sugar, and drank soda daily. She never questioned the health directives given to her by her doctors, and was never told that there might be a connection between her health issues and the diet that she was eating.. In 2002, when Hollie was just 27 years old and in her 38th week of pregnancy, she was diagnosed with an infiltrating ductal carcinoma. This is the most common type of breast cancer which affects some 80% of patients, and as its name suggests, the cancer had broken through the milk duct and was invading the surrounding tissues of the breast. Over time, invasive ductal carcinomas can spread to the lymph nodes and to other areas of the body. Hollies main tumor was 2.3 cm, with a second tumor measuring 0.6 cm. The larger tumor was a ...

AIM: The traditional architecture based classification system of ductal carcinoma in situ (DCIS) has been criticised on the grounds that individual lesions often show more than one pattern resulting in a large mixed category. New DCIS classification systems have emphasised the importance of cytological grade, which is reputed to be more uniformly expressed throughout a lesion. This study investigates the hypothesis that cytological heterogeneity is less common than architectural heterogeneity within DCIS lesions. METHODS: 121 cases of DCIS were graded as poorly, intermediately, or well differentiated according to a recently developed classification system that employs cytonuclear morphology as the major diagnostic criterion. Cases were categorised as pure when only one grade was present and as mixed if more than one grade was observed. Architecturally the cases were classified as solid, cribriform, micropapillary, or papillary and were described as pure if only one architectural pattern was ...

Different Names  Ductal carcinoma in-situ  Intraductal carcinoma  Non-invasive  Pre-cancer  Stage 0 Resource: Wikipedia.org

Here, we show that SOX11, an embryonic mammary marker that is normally silent in postnatal breast cells, is expressed in many oestrogen receptor-negative preinvasive ductal carcinoma in situ (DCIS) lesions. Mature mammary epithelial cells engineered to express SOX11 showed alterations in progenitor cell populations, including an expanded basal-like population with increased aldehyde dehydrogenase (ALDH) activity, and increased mammosphere-forming capacity. DCIS.com cells engineered to express SOX11 showed increased ALDH activity, which is a feature of cancer stem cells. The CD44+/CD24-/ALDH+ cell population was increased in DCIS.com cells that expressed SOX11. Upregulating SOX11 expression in DCIS.com cells led to increased invasive growth both in vitro and when they were injected intraductally in a mouse model of DCIS that recapitulates human disease. Invasive lesions formed sooner and tumour growth was augmented in vivo, suggesting that SOX11 contributes to the progression of DCIS to invasive ...

RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether surgery is more effective with or without gefitinib in treating ductal carcinoma in situ.. PURPOSE: This randomized phase II trial is studying how well gefitinib together with surgery works compared to surgery alone for the treatment of women with ductal carcinoma in situ of the breast. ...

The distribution of ductal carcinoma in situ DCIS grade in 4232 women and its impact on overdiagnosis in breast cancer screening. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.

Queenie - Patient: Breast Cancer > Ductal carcinoma in situ (DCIS) Patient Info: Currently in active treatment (initial surgery, receiving chemo rounds/radiation), Diagnosed: over 7 years ago, Female, Age: 74, Stage I

Rita - Patient: Breast Cancer > Ductal carcinoma in situ (DCIS) Patient Info: Currently in active treatment (initial surgery, receiving chemo rounds/radiation), Diagnosed: almost 7 years ago, Female, Age: 50, Stage 0

copland16 - Survivor: Breast Cancer > Ductal carcinoma in situ (DCIS) Patient Info: Finished active treatment less than 5 years ago, Diagnosed: over 9 years ago, Female, Age: 48, Stage II, HER2 Positive: No, ER Positive: Yes, PR Positive: Yes

penny364 - Survivor: Breast Cancer > Ductal carcinoma in situ (DCIS) Patient Info: Finished active treatment less than 5 years ago, Diagnosed: about 5 years ago, Female, Age: 71, Stage 0, HER2 Positive: No, ER Positive: Yes, PR Positive: Yes

fortysomething - Survivor: Breast Cancer > Ductal carcinoma in situ (DCIS) Patient Info: Finished active treatment less than 5 years ago, Diagnosed: over 11 years ago, Female, Age: 50

djmandy - Patient: Breast Cancer > Ductal carcinoma in situ (DCIS) Patient Info: Prefer not to answer/not applicable/unsure, Diagnosed: almost 10 years ago, Female, Age: 50, Stage 0

Dr Oz did a segment called Breast Cancer Alert: Could Early Diagnosis Be Dangerous? in which he discussed Ductal Carcinoma In Situ or DCIS. Some of the

Introduction Ductal carcinoma in situ (DCIS) is a common pre-invasive malignancy of the breast, representing approximately 20% of all breast cancer diagnoses...

niborflamingo - Patient: Breast Cancer > Invasive (Infiltrating) Ductal Carcinoma Patient Info: Currently in active treatment (initial surgery, receiving chemo rounds/radiation), Diagnosed: about 8 years ago, Female, Age: 70

hanife - Patient: Breast Cancer > Invasive (Infiltrating) Ductal Carcinoma Patient Info: Finished active treatment less than 5 years ago, Diagnosed: over 10 years ago, Female, Age: 61

We review relevant publications on ductal carcinoma in situ of the breast in the past three years and we discuss pattern of outcome lightened by new molecular approach and techniques of radiotherapy.

TY - JOUR. T1 - Ductal Carcinoma in Situ of the Breast. AU - Erickson, Lori A.. PY - 2017/12/1. Y1 - 2017/12/1. UR - http://www.scopus.com/inward/record.url?scp=85034619834&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=85034619834&partnerID=8YFLogxK. U2 - 10.1016/j.mayocp.2017.10.012. DO - 10.1016/j.mayocp.2017.10.012. M3 - Comment/debate. AN - SCOPUS:85034619834. VL - 92. SP - 1873. EP - 1874. JO - Mayo Clinic Proceedings. JF - Mayo Clinic Proceedings. SN - 0025-6196. IS - 12. ER - ...

Leukocytes, which mount antitumor immune responses, present a barrier and selective pressure in tumor progression (19). Innate immune responses do not rely on antigens for activation, represent the first-line of defense against pathogens and cancer, and are responsible for activating adaptive immunity. In normal breast, CD45+ leukocytes are relatively rare, but detectable in both stroma and within mammary ducts (20). In DCIS, leukocytes are abundant in the stroma surrounding the ducts (especially in high-grade and HER2+ lesions), but intraepithelial leukocytes are rarely detectable (21). Leukocytes also localize to sites of myoepithelial cell layer disruption/microinvasion (21). This limited interaction between leukocytes and cancer cells in DCIS may underlie a mechanism by which tumors evade immune surveillance. Therefore, in DCIS, tumors could still exist in the equilibrium phase, with immune escape likely occurring during or just prior to invasive transition (Fig. 1A).. Both, myeloid and ...

Breast: Secretory Ductal Carcinoma with t(12;15) ETV6/NTRK3, Authors: Stevan Knezevich. Published in: Atlas Genet Cytogenet Oncol Haematol.

RATIONALE: Diagnostic procedures, such as MRI, may help find ductal carcinoma in situ and find out how far the disease has spread.PURPOSE: This

Zamecnik, M. Atypical cystic lobules: an advancing edge of low-grade ductal carcinoma in situ?. Virchows Archiv 437, 469 (2000). https://doi.org/10.1007/s004280000253. Download ...

All structured data from the main and property namespace is available under the Creative Commons CC0 License; text in the other namespaces is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. ...

Invasive (Infiltrating) Ductal Carcinoma Pain Side Effects wildbill4809 - WhatNext.com - All over body pain, top of her head hurts in the hair folicals, tiredness, loss of appetite, sleepless nights, low grade fever of 99.1.

The differential expression of PDCD4 (in cancer cells) and miR-21 (in stromal cells) cannot alone form the basis for arguing that miR-21 is dynamically targeting PDCD4. Interestingly, we identified miR-21 in a subset of normal mammary glands and in some high-grade breast tumors - including pre-invasive DCIS lesions (ductal carcinoma in situ, considered the earliest form of breast cancer). We observed that miR-21 can indeed be expressed in normal epithelial and in cancer cells (Nielsen et al., 2014, Frontiers in Oncology ...

WILMINGTON, Del-AstraZen-eca announced in a news release that the FDA has approved Nolvadex (tamoxifen) to reduce the risk of invasive breast cancer in women with ductal carcinoma in situ (DCIS) following breast surgery and radiation. Nolvadex is the first medication to be approved for DCIS, which accounts for nearly 20% of all newly diagnosed breast cancers, the company said. 1

Most women usually opt for a lumpectomy with or without additional treatments such as for example radiation, hormonal therapy or chemotherapy. However, since the most DCIS lesions arent associated with formation of subsequent invasive tumors, chances are that many women identified as having DCIS are becoming over treated. Approximately 12-15 % of ladies diagnosed with DCIS create a subsequent invasive tumor within a decade after undergoing medical lumpectomy. Related StoriesCornell biomedical engineers develop very natural killer cells to destroy cancer cells in lymph nodesViralytics enters into scientific trial collaboration agreement with MSDMeat-rich diet may increase kidney tumor riskAs noted in the study, it is well known that normal cellular responses to stress are essential barriers to cancer development and therefore provide researchers with molecular candidates to greatly help identify lesions that wont progress to a malignancy.It is necessary that the very best use is made from ...

Investigating multiple samples (n={}25) from four patients we found an average of 5.6 ± 0.9 (mean ± SEM) chromosomal imbalances already present in DH. In the twelve DCIS lesions an average of 10.8 (±0.9) aberrations was identified with 14.8 (±0.8) aberrations in the four adjacent IDC lesions. The increasing number of chromosomal changes in parallel with the histopathological sequence corroborate the hypothesis, that the carcinomas may have developed through a sequential progression from normal to proliferative epithelium and eventually into carcinoma. However, heterogeneous results were identified in the multiple samples per entity from the same patient, demonstrated mainly in the DCIS samples in the chromosomal regions 6p, 9p, 11q, 16p and 17q, in the DH samples by 3p, 16p and 17q. This heterogeneous findings were most pronounced within the DH and was less in the DCIS and IDC samples. The only aberration consistently found in all samples - even in all DH samples - was amplification of the ...

This information is not intended to replace the advice of a doctor. Navigating Care disclaims any liability for the decisions you make based on this information. This information was sourced and adapted from Adapted from the National Cancer Institutes Physician Data Query (PDQ®) Cancer Information Summaries on www.cancer.gov. ...

Radiotherapy treatment (RT) after surgery for ductal carcinoma in situ (DCIS) has a major protective effect against recurrence more than 15 years later, according to the results of an international trial presented March 22 at the 8th European Breast Cancer Conference (EBCC-8).

Hi, My doctory just called me with the results of my biopsy. The report says APPROACHING the lowest grade of dcis. I asked my doctor if this means benign or malignant, and he said inbetween. I asked...

Ductal carcinoma in situ is the fourth most common cancer diagnosis in women. Some say its not really cancer. But you wouldnt know that based on how it is treated.. by Sue Rochman ...

Looking for JET-LUBE Anti Seize,Nonmetallic,Nuclear Grade? Graingers got your back. Clearance Price:$38.48. Easy ordering & convenient delivery. Log-in or register for your pricing.